Discover CME, tools, and guideline-focused education to improve your knowledge - and patient outcomes.
Translating Research Into Practice in Breast Cancer: Emerging Data and the Expanding Role of ADCs
Sara A. Hurvitz, MD, FACP
Tiffany Traina, MD
Clinical Evidence on Emerging Antigen-Directed Strategies in ES-SCLC
Ticiana Leal, MD
Beyond Checkpoint Blockade in SCLC: Emerging Antigen Targets and Treatment Strategies Across Disease Stages
Neal Ready, MD, PhD
Rationale of Emerging Antigen-Directed Strategies in Frontline ES-SCLC
Treatment Decisions That Matter: Live Tumor Board in Advanced Ovarian Cancer
Multiple dates available
Perioperative Immunotherapy in LA-HNSCC: From Evidence to Clinical Practice
Christophe Le Tourneau, MD, PhD
Marc Oliva, MD, PhD
Clear Skin, Clear Path: Transforming Psoriasis Care with Durable Biologic and Oral IL-23 Innovations
Linda Stein Gold, MD
Lakshi Aldredge, MSN, ANP-BC
Najat M. Watch, PA
Precision in Practice—Bringing Targeted Therapy to mHSPC
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
On the Horizon: Emerging Antigen-Directed Strategies Across Disease Stage
Advancing Acromegaly Care: Diving Deeper Into Diagnosis, Guideline Application, and Emerging Therapies—A Fireside Chat With Expert Perspectives
Maria Fleseriu, MD, FACE
Beverly MK Biller, MD, FACP
Mark Gurnell, MD
The Evidence Base: Key Trials and Emerging Data
From Abstract to Action in Breast Cancer: Interpreting Recent Data on Oral SERDs and Endocrine Targeting Strategies
Aditya Bardia, MD, MPH, FASCO
Erica L. Mayer, MD, MPH
Cracking the Code: Risk Stratification Guidelines to Identify High-Risk Patients
ADT Intensification in Biochemically Recurrent Prostate Cancer: When to Act
Building the Team: Integrating Immunotherapy Into Multidisciplinary Care
The Next Generation of Care: New Treatment Frontiers in Immunotherapy-Resistant Advanced Squamous NSCLC
September 12, 2026 Seoul
Translating Evidence on TROP2-Directed ADCs Into Global Practice in Metastatic TNBC
Javier Cortes, MD, PhD
What’s Next for TROP2-Directed ADCs in TNBC?
Comparing First-Line TROP2-Directed ADCs in Metastatic TNBC: Latest Clinical Evidence
Managing Adverse Events Associated With TROP2-Directed ADCs in Metastatic TNBC
The Case for Change: Why Perioperative Immunotherapy Matters in LA HNSCC
The Power of Timing: Therapies That Change Outcomes
Current Unmet Needs in First-Line Treatment of Metastatic TNBC
Chairperson’s Perspective: Incorporating Novel Treatment Options for Schizophrenia Into Clinical Practice - Overcoming Clinical Inertia
Jose Rubio, MD
Precision Through the Continuum: Applying Biomarker-Guided Therapies in Ovarian Cancer
Susana Campos, MD, MPH
Robert Coleman, MD, FACOG
Debra Richardson, MD
The Future of mCSPC: Molecular Profiling and Biomarker-Directed Therapies
Neeraj Agarwal, MD, FASCO
Rana McKay, MD
Loading...
We're glad to see you're enjoying Prova Education… but how about a more personalized experience?
Press cancel to remain on Prova Education. Press the link below or the continue button to keep going.